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Abstract
Background: Malignant melanoma as one of the most common cancers is currently spreading worldwide. Regarding after-effect
of advanced treatments, using natural products has attracted much attention. Flavonoids, polyphenol compounds rich in diet, are
being considered for their therapeutic preventive features. Fyn gene, a member of the protein tyrosine kinase oncogene family, has
become an important target for therapy goals.
Objectives: The aim of this study was to assess Fyn gene expression after treatment of melanoma cells with myricetin.
Methods: In this study, the melanoma cells were treated with different concentrations of myricetin (0 to 100 µM) and their via-
bility was determined by the methylthiazolyl diphenyl-tetrazolium bromide (MTT) assay, also the expression of Fyn gene in treated
cells with selected concentrations of myricetin (0, 20, 40, 50, and 60µM) was detected by real time quantitative polymerase chain
reaction (qPCR).
Results: The current investigation showed that treatment of A375 melanoma cells with the dietary flavonoid myricetin (3, 5, 7-
trihydroxy-2-(3, 4, 5,-trihydroxy phenyl)-4- chromenone), resulted in decreased cell viability and increased expression of Fyn gene.
The MTT assay analysis of exposed cells with different concentrations of myricetin showed that up to 25 µM of myricetin had no
cytotoxicity effect on A375 cells, also with increasing of myricetin concentration, the repression of cell proliferation developed as
well.
Conclusions: Real time qPCR analysis of Fyn expression in exposed cells with various concentration of myricetin leads to overex-
pression of this gene, dose dependently. Through this research, it was determined that myricetin with its anti-proliferative potential
could suppress the development of cancer cells. On the other hand, since Fyn kinase could be involved in tumorigenesis of some
cancer cells, it could be concluded that myricetin could effect the carcinogenicity of Fyn function in melanoma cells.
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1. Background
Cancer, as a leading cause of death globally, has been
on the spotlight for many researchers. According to the
American cancer society, melanoma is considered among
the most common cancers worldwide and regarding the
adaption of new lifestyle, the occurrence of malignant
melanoma is increasing, leading to high mortality rates (1).
In the recent decades, due to harmful health effect
of usual cancer treatment, many researches have been
done to constitute natural substances for medicine pur-
poses. Flavonoids, natural compound with low molecular
weight, on account of pharmacological properties, such
as anticancer, antioxidant, anti-inflammatory, and anti-
angiogenesis activities, are considered as one of the most
interesting subjects in many studies (2). A basic c6-c3-c6
phenyl-benzopyran backbone is shared in all flavonoids
and different groups of flavonoids, based on the position
of B ring relative to C ring, C2-C3 double bound, and 3-OH
groups, have been classified (3) (Figure 1) (4).
Among these natural products, myricetin is one of the
best compounds with inhibitory and anti-oxidant abilities
(Figure 2) (5).
Myricetin, present in different kinds of fruits, could
modulate the activity of important signaling molecules,
such as protein kinase (ERK1/2) in lung cancer cells (6) and
kinase B (Akt) in cervical and lung cancer cell lines (7, 8).
These pathways could influence growth and survival of
cancer cells, and result in generation and cell cycle pro-
gression.
Some transcriptional factors, like NF-κB, AP-1 and
STAT3, are key factors in cell transduction, the function of
which is inhibited by myricetin (9, 10).
Two classes of tyrosine kinases (TKs), important classes
of molecules in human biology are receptor and non-
receptor TKs. Receptor TKs, involving epidermal growth
factor receptor (EGFR), vascular endothelial growth factor
receptor (VEGFR), and mesenchymal epithelial transition
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Figure 1. Classification of Flavonoids
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Figure 2. Myricetin Structure
factor (c-MET), are membrane proteins receiving signals
from lignds. Non receptor TKs include members of fami-
lies, such as Abl, Src, and focal adhesion kinase that by be-
ing activated, could stimulate downstream signals to pro-
cess growth and motility of cancer cells, the activation of
which is firmly organized (11).
The Src families participate in diverse signaling pro-
cesses, involving mitogenesis, T- and B-cell activation in ad-
dition to being shared in several human carcinomas, such
as breast, lung, and colon cncer (12).
Fyn, a member of the Src family, could phosphorylate
tyrosine residues of targets in different signaling pathway,
overexpressed in a variety of cancers, including glioblas-
toma multiform, squamous cell carcinoma of the head and
neck, and prostate cancer (13). There is a relationship be-
tween the inhibition of Fyn and decreased cell growth. In
the PI3K/Akt/PKB pathway, Fyn acts as a mediator of growth
factor, and induces the anti-apoptotic activity of Akt/PKB
(14). Some studies determined that Fyn overexpression
promotes anti-apoptotic activity of Akt. On the other hand,
activation of Akt in some cancers, such as prostate cancer,
is common. Further studies are required to elucidate the
mechanism of Fyn function and dysregulation of Akt activ-
ity (15).
Also, it has been reported that Fyn has a role in
epithelial-mesenchymal transition (EMT) process, includ-
ing loss of cell adhesion, increase of cell motility, and
change from E-cadherin to N-cadherin expression (16).
2. Methods
2.1. Reagents
Myricetin and methylthiazolyl diphenyl-tetrazolium
bromide (MTT) powder were purchased from sigma
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Aldrich. The A375 cell line was prepared from the pasture
institution. Fetal bovine serum (FBS), phosphate-buffered
saline (PBS) tablet, penicillin-streptomycin, trypsin-EDTA,
and first strand cDNA synthesis were obtained from In-
vitrogen. The RNA extraction kit was prepared from gene
all. Furthermore, qPCR Green Master with low ROX was
purchased from jena bioscience. Primers were prepared
from Takapouzist. Culture Media (DMEM high glucose)
were obtained from biosera.
2.2. Cell Culture
A375 cells were cultured in DMEM high glucose, con-
taining 10% (v/v) FBS and 1% penicillin-streptomycin. The
cells were incubated at 37° in a humidified atmosphere of
5% CO2. Confluent cultures of melanoma cells were rinsed
in phosphate-buffered saline (PBS) and removed from the
flask using 0.25% trypsin/EDTA, neutralized with FBS and
the cell suspension was prepared.
2.3. Cell Counting
To find the doubling time of melanoma cells, 8000
cells were placed on each well in a 96-well plate. Dur-
ing one week at different periods of time, the cells were
counted and the data were recorded (17).
2.4. Determination of Cell Viability
Cell viability was detected by using the micro culture
tetrazolium technique (MTT). This quantitative measure
provides the number of viable cells by determining the
amount of formazan crystals produced by metabolic activ-
ity in treated versus control cells (17).
2.5. Treatment of Cells with Myricetin
For RNA extraction, 3 × 105 cells were seeded in 6-
well plates and were exposed to various concentrations of
myricetin (control, 0.1% Ethanol, 20, 40, 50, and 60 µM)
for 48 hours. The concentrations were chosen based on ac-
quired IC50 from MTT results. The experiments were done
in triplicates.
2.6. Real Time qPCR
Real-time qPCR was used to determine the expression
of Fyn gene after 48 hours of treatment. Total RNA was
extracted using Trizol (Gene All), according to the manu-
facturer’s instructions, and then quantified. Its concentra-
tion was detected spectrophotometrically at 260 nm (Nan-
odrop 1000 UV-Vis Spectrophotometer). First strand com-
plementary DNAs (cDNA) were synthesized from 5 ng of
the isolated RNA by random Hexamer primer using Re-
vertAid first strand cDNA synthesis kit (Fermentase), and
used as templates for real time qPCR. The expression of
mRNAs was determined quantitatively using qPCR green
master with lowROX kit. The PCR was performed on a fi-
nal volume of 20 µL, containing 1 µL of cDNA, 250 nM of
each primer, and 10 µL of qPCR Green Master, with ABI
7500 real time step one plus system (Applied Biosystems,
USA). The primers used for Eva green real time qPCR were
as follows: Fyn Forward: 5’-ATTGCTGACTTCGGATTGGC-3’,
Fyn Reverse: 5’-TGGCACTCTTCCTTTGGTGA-3’, GAPDH For-
ward: 5’-CAATGACCCCTTCATTGACC-3’, and GAPDH Reverse:
5’- TGGAAGATGGTGATGGGATT-3’.
The samples underwent 40 cycles consisting of the fol-
lowing steps: initial denaturation at 95°C for 2 minutes,
followed by a set cycle of denaturation at 95°C for 15 sec-
onds, annealing and elongation temperature at 60°C for
1 minute. Fold increment of gene, based on the pfaﬄ
method, at different concentrations was calculated by nor-
malizing its expression level to that of the glyceralde-
hyde 3-Phosphate dehydrogenase (GAPDH) gene, which
was used as an internal control. The formula was as below:
Fold difference = (E target) ∆Ct target / (E normalizer)
∆Ct normalizer
E = efficiency from standard curve E = 10 (-1 /slope)
∆Ct target = Ct GOI c - Ct GOI s
∆Ct normalizer = Ct norm c- Ct norm s. (18)
2.7. Statistical Analysis
All experiments reported in this study were accom-
plished independently 3 times. Results are expressed as
mean± standard deviation (SD). Statistical analyses of the
significance of differences among values were carried out
by one-way analysis of variance (ANOVA), using the PRISM
software. Values of P < 0.05 were considered statistically
significant.
2.8. Ethical Issue
This study was in accordance with the Helsinki dec-
laration, approved by the regional institution number:
IR.QUMS.REC.1394.173 Qazvin University of medical science.
3. Results
3.1. Doubling Time Distribution
The results of counting melanoma cells (A375) ac-
knowledged that the doubling time of cells was 17 hours
(17).
3.2. The MTT Assay
To ascertain the inhibitory effect of myricetin on
melanoma cells, A375 cells were treated with different con-
centrations (0 to 100 µM) for 48 hours. Due to the current
findings, with increasing concentration of myricetin, cell
proliferation was reduced. On the other hand, the IC50 of
myricetin for 48 hours was 40 µM (Figure 3) (17).
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Data are presented as the mean± SD of the 5 experiments (*P < 0.05, ***P < 0.0001)
versus the control group.
3.3. Treatment of Cells with Myricetin
As shown in Figure 4, 48 hours of exposure of cells to
myricetin resulted in reduction of cell proliferation, dose
dependently.
3.4. The mRNA Expression of Fyn
Real time qPCR was used to detect the expression of Fyn
gene when melanoma cells (A375) were cultured in DMEM
medium supplemented with different concentrations of
myricetin for 48 hours. The mRNA expression of Fyn was in-
creased in the treated group, dose dependently, with the re-
sults being significant compared to the 0.1% Ethanol group
(P < 0.05) (Figure 5).
4. Discussion
Myricetin, rich in fruits and vegetables, is identi-
fied to have different biological influence with multiple
mechanisms. In this study, the authors determined that
myricetin has an antiproliferative effect on melanoma
cells so that it could suppress the growth of melanoma
cells, and increase the expression of Fyn mRNA in these
cells, which had been decreased previously (before treat-
ment as a sign of advanced cancer).
In the last few years, considerable advancement has
been made in melanoma treatment, however, the pros-
perous therapy is still a challenge. The activation of PI3K/
Akt signaling pathway, in relation with Fyn, is associated
with cancer progression in various cancer types, includ-
ing melanoma. Research literature emphasizes the signif-
icance of natural compounds in cancer suppression and
therapy (19).
The Src has been identified as an important oncogene,
yet little attention has been paid to its family members, in-
cluding Fyn. Since Akt activation is common in many can-
cers, including prostate cancer, Fyn overexpression results
in promotion of Akt anti-apoptotic activity (13). In breast
cancer, Fyn expression is dependent on PI3K function. In
this way, the Ras/ PI3K/ Akt pathway demonstrates overex-
pression of Fyn in cancer. These results support the ad-
vancement of therapeutic strategies targeting Fyn to sup-
press invasion and migration of tumor cells (20).
The current results determined that myricetin has an
inhibitory effect on proliferation of melanoma cells (A375).
The IC50 of myricetin for 24, 48, and 72 hours was 50, 40,
and 35 µM respectively (17). In this study, the researchers
concluded that exposure of cells with different concentra-
tions of myricetin (0, 20, 40, 50, and 60µM) after 48 hours,
developed the expression of Fyn at mRNA level, dose de-
pendently.
Pathologically, it has been demonstrated that low ex-
pression level of FRK protein could be involved in tumori-
genesis and cell movement of human cervical cancer, so
that FRK expression may be performed as a hopeful predic-
tive indicator of this malignancy (21). In another research,
it was shown that Fyn has a key role in signal transforma-
tion and proliferation of neuroblastoma cells. Therefore,
the results detected that Fyn kinase expression suppresses
tumor progression and metastasis (22). In agreement with
these studies and based on the multifunctional role of Fyn
in various cancer cells, it has been implied that in cancer
cells like lung cancer, Fyn-related kinase led to cell growth,
invasion, and colony formation of cells (23), while in some
cancer cells, including colon, breast and hepatocyte can-
cer, the expression of Fyn kinase increased (24).
Overall, the achieved data on myricetin demonstrates
its therapeutic effect of a multipurpose nature. The poten-
tial of myricetin in down-regulation of the oncogenic sig-
naling pathways, such as PI3K, AKT/mTOR/p70SK and GSK-
beta catenin pathways, could be a confirmed approach in
treating human malignancies (25). Fyn, an oncoprotein,
plays a critical role in the development of skin cancer un-
der UVB-induced circumstances. Aberrantly, expression of
Fyn in many human skin cancer cases, makes it an ideal
target in treatment of skin cancer. Myricetin applies its
chemo preventive effect against skin cancer by targeting
the Fyn protein. To block UVB-mediated skin cancer, the
molecular mechanism of myricetin involves the inhibition
of Fyn protein, regulation of Cox-2 expression, and reduc-
tion in phosphorylation of MAPKs (26).
Ye Li et al. in 2016 detected that myricetin could reduce
pro-inflammatory cytokines like IL-6, IL-1β, and TNF-α to
evaluate APC in mice. Also myricetin down regulates the
phosphorylated P38 MAPK/ AKt/ m TOR signaling pathways
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Figure 4. Treated Cells with Different Concentrations of Myricetin for 48 Hours
A, B, C, D, E, and F show treated cells with different concentrations of myricetin including: 0, 0.1% ethanol, 20, 40, 50, and 60µMmyricetin, respectively.
Figure 5. Calibrated Result of Real Time qPCR, Before and After Treatment with Dif-






















Each bar denotes the mean± SD of 6 experiments (***P < 0. 001, **P < 0.01 versus
0.1% ethanol group).
to inhibit adenomatous polyps (27). Myricetin with high
cytotoxicity effect has chemo preventive impact on ovar-
ian cancer cells like OVCAR-3 and A2780/ CP70, which could
prompt apoptosis through BCL-2 family proteins. In this
regard, myricetin could induce P53, which plays an impor-
tant role in BCL-2 family protein dependent apoptosis in
cancer cells with no efficacy in promoting apoptosis in nor-
mal cells (28).
In some studies it has been shown that FRK functions as
a tumor repressor. For instance, in breast cancer cells, the
methylation of CPG sites in the promoter region of tumor
suppressor was observed, and DNA methylation decreased
the expression of FRK in a subset of breast cancer cells (29).
In this study, the researchers determined that
myricetin could suppress the proliferation of melanoma
cells, on the other hand, it did not have any toxicity effect
up to 25 µM. Real time qPCR showed that myricetin could
increase the expression of Fyn at mRNA level, so that
increasing the concentration of myricetin, developed Fyn
expression, as a tumor repressor, not noticeably.
Accumulated data have suggested that flavonoids, by
directly interacting with protein kinases, could utilize
their bioactivity to modulate intracellular signaling cas-
cades and carcinogenesis. Different flavonoids, including
myricetin, could bind to the ATP-binding site of Fyn (30).
Since flavonoids could target multiple signaling pathways
simultaneously, it is possible that cross-reactivity with
unrelated ATP-binding proteins results in adverse conse-
quences that cause many protein kinase inhibitors to fail
(31).
On the other hand, in the signaling pathway, almost all
components were identified, yet there is a possibility that
they could activate, modify, or inhibit each other or may
be involved in cross-reactivity to other pathways. For in-
stance, GSK-3β interacts with multiple signaling pathways,
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such as PTEN/ PI3K/ AKt/ mTOR, Ras/ Raf, which could be
regulated by tyrosine kinases, such as Src, Fyn, and Pro-
tein Tyrosine Kinase 2 beta (PYK2) (32), thus, these mu-
tual reactions reveal that signaling pathways in malignant
melanoma may compensate each other to make resistance
to molecular-targeted therapy (33). Although it is hard
to prognosticate the physiological or pharmacological im-
portance of the inhibition potential of flavonoids, deter-
mining the expression of Fyn protein by western blotting
could acknowledge our results on the basis of myricetin
potential in decreasing the oncogenic effect of Fyn on ma-
lignant melanoma cells.
Acknowledgments
This work was supported by funds from the student re-
search committee of Qazvin University of Medical Science
with grant application number 28/20/11501.
Footnote
Conflicts of Interests: None declared.
References
1. Gandhi SA, Kampp J. Skin Cancer Epidemiology, Detection,
and Management. Med Clin North Am. 2015;99(6):1323–35. doi:
10.1016/j.mcna.2015.06.002. [PubMed: 26476255].
2. Jaime A, Remsberg CM, Takemoto JK, Vega-Villa KR, Andrews PK, Sayre
CL, et al. Polyphenols and flavonoids : an overview. 2013.
3. Pinheiro PF, Justino GC. Structural analysis of flavonoids and related
compounds-a review of spectroscopic applications. INTECH Open Access
Publisher; 2012.
4. Ramos S. Effects of dietary flavonoids on apoptotic pathways related
to cancer chemoprevention. J Nutr Biochem. 2007;18(7):427–42. doi:
10.1016/j.jnutbio.2006.11.004. [PubMed: 17321735].
5. Yao Y, Lin G, Xie Y, Ma P, Li G, Meng Q, et al. Preformulation studies of
myricetin: a natural antioxidant flavonoid. Pharmazie. 2014;69(1):19–
26. [PubMed: 24601218].
6. Shih YW, Wu PF, Lee YC, Shi MD, Chiang TA. Myricetin suppresses inva-
sion and migration of human lung adenocarcinoma A549 cells: pos-
sible mediation by blocking the ERK signaling pathway. J Agric Food
Chem. 2009;57(9):3490–9. doi: 10.1021/jf900124r. [PubMed: 19326946].
7. Ying X, Chen X, Feng Y, Xu HZ, Chen H, Yu K, et al. Myricetin en-
hances osteogenic differentiation through the activation of canoni-
cal Wnt/beta-catenin signaling in human bone marrow stromal cells.
Eur J Pharmacol. 2014;738:22–30. doi: 10.1016/j.ejphar.2014.04.049.
[PubMed: 24876056].
8. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann
MP, et al. Structural determinants of phosphoinositide 3-kinase
inhibition by wortmannin, LY294002, quercetin, myricetin, and
staurosporine. Mol Cell. 2000;6(4):909–19. doi: 10.1016/S1097-
2765(05)00089-4. [PubMed: 11090628].
9. Young MR, Yang HS, Colburn NH. Promising molecular targets
for cancer prevention: AP-1, NF-kappa B and Pdcd4. Trends Mol
Med. 2003;9(1):36–41. doi: 10.1016/S1471-4914(02)00009-6. [PubMed:
12524209].
10. Chan KS, Sano S, Kiguchi K, Anders J, Komazawa N, Takeda J, et
al. Disruption of Stat3 reveals a critical role in both the initiation
and the promotion stages of epithelial carcinogenesis. J Clin Invest.
2004;114(5):720–8. doi: 10.1172/JCI21032. [PubMed: 15343391].
11. Boggon TJ, Eck MJ. Structure and regulation of Src family kinases.
Oncogene. 2004;23(48):7918–27. doi: 10.1038/sj.onc.1208081. [PubMed:
15489910].
12. Cˇalic´, M , Jelic´, D , Antolovic´, R , Nujic´, K , Marjanovic´, N , Stupin
Polancˇec, D , et al. Flavonoids as inhibitors of lck and fyn kinases. Croat
Chem Acta. 2005;78(3):367–74.
13. Posadas EM, Al-Ahmadie H, Robinson VL, Jagadeeswaran R, Otto K,
Kasza KE, et al. FYN is overexpressed in human prostate cancer. BJU
Int. 2009;103(2):171–7. doi: 10.1111/j.1464-410X.2008.08009.x. [PubMed:
18990162].
14. Chen R, Kim O, Yang J, Sato K, Eisenmann KM, McCarthy J, et al.
Regulation of Akt/PKB activation by tyrosine phosphorylation. J Biol
Chem. 2001;276(34):31858–62. doi: 10.1074/jbc.C100271200. [PubMed:
11445557].
15. Liao Y, Grobholz R, Abel U, Trojan L, Michel MS, Angel P, et al. Increase
of AKT/PKB expression correlates with gleason pattern in human
prostate cancer. Int J Cancer. 2003;107(4):676–80. doi: 10.1002/ijc.11471.
[PubMed: 14520710].
16. Vernon AE, LaBonne C. Tumor metastasis: a new twist on epithelial-
mesenchymal transitions. Curr Biol. 2004;14(17):R719–21. doi:
10.1016/j.cub.2004.08.048. [PubMed: 15341765].
17. Abdolmaleki F, Gheibi N, Ahmadpour_ Yazdi H. The inhibitory effect
of myricetin in melanoma cells (A375). Novelty Biomed. 2017;5(3):104–8.
18. Pfaﬄ MW. A-Z of Quantitative PCR. International University Line (IUL);
2004.
19. Gajos-Michniewicz A, Czyz M. Modulation of WNT/beta-catenin path-
way in melanoma by biologically active components derived from
plants. Fitoterapia. 2016;109:283–92. doi: 10.1016/j.fitote.2016.02.002.
[PubMed: 26851176].
20. Yadav V, Denning MF. Fyn is induced by Ras/PI3K/Akt signaling
and is required for enhanced invasion/migration. Mol Carcinog.
2011;50(5):346–52. doi: 10.1002/mc.20716. [PubMed: 21480388].
21. Zhang X, Li F, Zhu PL. Fyn-related kinase expression predicts favor-
able prognosis in patients with cervical cancer and suppresses malig-
nant progression by regulating migration and invasion. Biomed Phar-
macother. 2016;84:270–6. doi: 10.1016/j.biopha.2016.09.042. [PubMed:
27665472].
22. Berwanger B, Hartmann O, Bergmann E, Bernard S, Nielsen D, Krause
M, et al. Loss of a FYN-regulated differentiation and growth arrest
pathway in advanced stage neuroblastoma. Cancer Cell. 2002;2(5):377–
86. doi: 10.1016/S1535-6108(02)00179-4. [PubMed: 12450793].
23. Chen JS, Hung WS, Chan HH, Tsai SJ, Sun HS. In silico identifica-
tion of oncogenic potential of fyn-related kinase in hepatocellular
carcinoma. Bioinformatics. 2013;29(4):420–7. doi: 10.1093/bioinformat-
ics/bts715. [PubMed: 23267173].
24. Goel RK, Lukong KE. Understanding the cellular roles of Fyn-
related kinase (FRK): implications in cancer biology. Cancer Metas-
tasis Rev. 2016;35(2):179–99. doi: 10.1007/s10555-016-9623-3. [PubMed:
27067725].
25. Devi KP, Rajavel T, Habtemariam S, Nabavi SF, Nabavi SM. Molecu-
lar mechanisms underlying anticancer effects of myricetin. Life Sci.
2015;142:19–25. doi: 10.1016/j.lfs.2015.10.004. [PubMed: 26455550].
26. Jung SK, Lee KW, Byun S, Kang NJ, Lim SH, Heo YS, et al. Myricetin
suppresses UVB-induced skin cancer by targeting Fyn. Cancer Res.
2008;68(14):6021–9. doi: 10.1158/0008-5472.CAN-08-0899. [PubMed:
18632659].
27. Li Y, Cui SX, Sun SY, Shi WN, Song ZY, Wang SQ, et al. Chemopre-
vention of intestinal tumorigenesis by the natural dietary flavonoid
myricetin in APCMin/+ mice. Oncotarget. 2016;7(37):60446–60. doi:
10.18632/oncotarget.11108. [PubMed: 27507058].
28. Huang H, Chen AY, Ye X, Li B, Rojanasakul Y, Rankin GO, et al. Myricetin
inhibits proliferation of cisplatin-resistant cancer cells through a
p53-dependent apoptotic pathway. Int J Oncol. 2015;47(4):1494–502.
doi: 10.3892/ijo.2015.3133. [PubMed: 26315556].
6 Biotech Health Sci. 5(1):e14484.
Abdolmaleki F et al.
29. Bagu ET, Miah S, Dai C, Spriggs T, Ogunbolude Y, Beaton E, et al. Re-
pression of Fyn-related kinase in breast cancer cells is associated with
promoter site-specific CpG methylation. Oncotarget. 2017;8(7):11442–
59. doi: 10.18632/oncotarget.14546. [PubMed: 28077797].
30. Hou DX, Kumamoto T. Flavonoids as protein kinase inhibitors for
cancer chemoprevention: direct binding and molecular modeling.
Antioxid Redox Signal. 2010;13(5):691–719. doi: 10.1089/ars.2009.2816.
[PubMed: 20070239].
31. Bogoyevitch MA, Fairlie DP. A new paradigm for protein kinase
inhibition: blocking phosphorylation without directly target-
ing ATP binding. Drug Discov Today. 2007;12(15-16):622–33. doi:
10.1016/j.drudis.2007.06.008. [PubMed: 17706543].
32. McCubrey JA, Rakus D, Gizak A, Steelman LS, Abrams SL, Lert-
piriyapong K, et al. Effects of mutations in Wnt/beta-catenin, hedge-
hog, Notch and PI3K pathways on GSK-3 activity-Diverse effects
on cell growth, metabolism and cancer. Biochim Biophys Acta.
2016;1863(12):2942–76. doi: 10.1016/j.bbamcr.2016.09.004. [PubMed:
27612668].
33. Clevers H. Wnt/beta-catenin signaling in development and disease.
Cell. 2006;127(3):469–80. doi: 10.1016/j.cell.2006.10.018. [PubMed:
17081971].
Biotech Health Sci. 5(1):e14484. 7
